伴发癌症的缺血性卒中患者血液中具有特定的miRNA-mRNA网络,且随缺血性卒中机制而异
研究比较伴癌症缺血性卒中(CS,n=42)、单纯卒中(SO,n=41)、单纯癌症(n=28)及血管危险因素匹配对照(n=30)的外周血转录组,发现CS与SO间有2085个mRNA和31个miRNA差异表达,心源性栓塞与非心源性栓塞CS各有特异性miRNA-mRNA调控对和共表达模块,15基因面板在验证队列中分类CS的准确率为81%、SO为71%。
要点
- 伴癌症卒中与单纯卒中间有2085个mRNA和31个miRNA差异表达。
- 心源性栓塞与非心源性栓塞伴癌症卒中各有122和35个miRNA-mRNA调控对。
- 15基因面板在验证队列中正确分类81%的伴癌症卒中和71%的单纯卒中。
核心结论
- 伴癌症卒中与单纯卒中、以及伴癌症卒中的不同缺血性卒中病因间存在独特的mRNA和miRNA转录组架构。
- 心源性栓塞与非心源性栓塞伴癌症卒中显示出独特的共表达网络和潜在主调控因子。
- 这些发现可能有助于区分伴癌症卒中与单纯卒中,并识别隐源性伴癌症卒中患者的缺血性卒中病因。
研究设计与样本
- 研究纳入伴癌症缺血性卒中患者42例、单纯卒中患者41例、单纯癌症患者28例及血管危险因素匹配对照30例。
- 对mRNA-Seq和miRNA-Seq数据采用线性回归模型分析,识别差异表达基因及miRNA-mRNA调控对。
- 网络水平分析识别伴癌症卒中中卒中病因特异性反应;生物标志物面板在推导队列(n=50)构建、验证队列(n=33)验证。
主要发现
- 伴癌症卒中与单纯卒中之间有2085个mRNA和31个miRNA差异表达。
- 伴癌症卒中中心源性栓塞和非心源性栓塞分别关联122和35个miRNA-mRNA调控对,以及5和3个共表达基因模块。
- 补体、生长因子和免疫/炎症通路在伴癌症卒中的不同缺血性卒中病因间存在差异。
- 由推导队列(n=50)构建的15基因面板在验证队列(n=33)中正确分类81%的伴癌症卒中和71%的单纯卒中参与者。
- 另一15基因面板在交叉验证中正确识别13/13例心源性栓塞伴癌症卒中和11/11例非心源性栓塞伴癌症卒中参与者的病因;16例隐源性伴癌症卒中参与者中11例被预测为心源性栓塞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Approximately half of ischemic strokes (IS) in cancer patients are cryptogenic, with many presumed cardioembolic. We evaluated whether there were specific miRNA and mRNA transcriptome architectures in peripheral blood of IS patients with and without comorbid cancer, and between cardioembolic versus noncardioembolic IS etiologies in comorbid cancer. METHODS: We studied patients with cancer and IS (CS; n = 42), stroke only (SO; n = 41), and cancer only (n = 28), and vascular risk factor-matched controls (n = 30). mRNA-Seq and miRNA-Seq data, analyzed with linear regression models, identified differentially expressed genes in CS versus SO and in cardioembolic versus noncardioembolic CS, and miRNA-mRNA regulatory pairs. Network-level analyses identified stroke etiology-specific responses in CS. RESULTS: A total of 2,085 mRNAs and 31 miRNAs were differentially expressed between CS and SO. In CS, 122 and 35 miRNA-mRNA regulatory pairs, and 5 and 3 coexpressed gene modules, were associated with cardioembolic and noncardioembolic CS, respectively. Complement, growth factor, and immune/inflammatory pathways showed differences between IS etiologies in CS. A 15-gene biomarker panel assembled from a derivation cohort (n = 50) correctly classified 81% of CS and 71% of SO participants in a validation cohort (n = 33). Another 15-gene panel correctly identified etiologies for 13 of 13 CS-cardioembolic and 11 of 11 CS-noncardioembolic participants upon cross-validation; 11 of 16 CS-cryptogenic participants were predicted cardioembolic. INTERPRETATION: We discovered unique mRNA and miRNA transcriptome architecture in CS and SO, and in CS with different IS etiologies. Cardioembolic and noncardioembolic etiologies in CS showed unique coexpression networks and potential master regulators. These may help distinguish CS from SO and identify IS etiology in cryptogenic CS patients. ANN NEUROL 2024;96:565-581.
引用
- Knepp B, Navi BB, Rodriguez F, et al. Ischemic Stroke with Comorbid Cancer Has Specific miRNA-mRNA Networks in Blood That Vary by Ischemic Stroke Mechanism. Ann Neurol. 2024. PMID: 38874304. doi:10.1002/ana.26997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。